Theratechnologies Buchwert je Aktie
Was ist das Buchwert je Aktie von Theratechnologies?
Buchwert je Aktie von Theratechnologies, Inc. ist -0.37
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf TSX im Vergleich zu Theratechnologies
Was macht Theratechnologies?
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.
Unternehmen mit buchwert je aktie ähnlich Theratechnologies
- Deinove SA hat Buchwert je Aktie von -0.38
- RCF Acquisition hat Buchwert je Aktie von -0.37
- Target Insurance () hat Buchwert je Aktie von -0.37
- Schultze Special Purpose Acquisition Corp II hat Buchwert je Aktie von -0.37
- Progenity hat Buchwert je Aktie von -0.37
- Tiscali Spa hat Buchwert je Aktie von -0.37
- Theratechnologies hat Buchwert je Aktie von -0.37
- Letho Resources hat Buchwert je Aktie von -0.37
- Bard Ventures hat Buchwert je Aktie von -0.37
- Banyan Acquisition hat Buchwert je Aktie von -0.37
- Carmat SA hat Buchwert je Aktie von -0.37
- Enphys Acquisition hat Buchwert je Aktie von -0.37
- Scout Security hat Buchwert je Aktie von -0.36